Cargando…

Hormonal Receptors, Human Epidermal Growth Factor Receptor-2 and Triple Negative Immunohistochemical Typing in Women with Breast Cancer in Kampala, Uganda

BACKGROUND: The expression of estrogen and progesterone receptors (ER and PR) and human epidermal growth factor receptor-2 (HER2) has been reported to have an invaluable prognostic role. The aim of this study was to determine the expression of ER, PR and HER2 in women with breast cancer (BC) in Kamp...

Descripción completa

Detalles Bibliográficos
Autores principales: Mlole, Angela T, Yahaya, James J, Othieno, Emmanuel, Kalungi, Sam, Okwi, Andrew L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745719/
https://www.ncbi.nlm.nih.gov/pubmed/33343201
http://dx.doi.org/10.2147/IJWH.S270082
_version_ 1783624660609400832
author Mlole, Angela T
Yahaya, James J
Othieno, Emmanuel
Kalungi, Sam
Okwi, Andrew L
author_facet Mlole, Angela T
Yahaya, James J
Othieno, Emmanuel
Kalungi, Sam
Okwi, Andrew L
author_sort Mlole, Angela T
collection PubMed
description BACKGROUND: The expression of estrogen and progesterone receptors (ER and PR) and human epidermal growth factor receptor-2 (HER2) has been reported to have an invaluable prognostic role. The aim of this study was to determine the expression of ER, PR and HER2 in women with breast cancer (BC) in Kampala, Uganda. METHODS: Expression of ER, PR and HER2 was determined immunohistochemically. Logistic regression was performed to determine the effect of the independent factors in predicting the risk of not expressing the breast markers. A two-tailed p<0.05 was regarded to be statistically significant. RESULTS: ER, PR and HER2 were expressed in 53.4%, 46.6% and 18.5%, respectively. ER and PR co-expression was present in 42.7% and 37.9% patients had triple negative breast cancer (TNBC). Age was an independent predictor of expression of ER (AOR = 0.18, 95% CI = 0.062–0.541, p = 0.002) and PR (AOR = 0.35, 95% CI = 0.129–0.968, p = 0.043). CONCLUSION: The majority of patients in this study had less than 50 years with high tumour grade. Interestingly, most of them had high expression of HER2 with TNBC which are molecular subtypes of BC with poor prognosis. Age was an independent predictor of expression of both ER and PR.
format Online
Article
Text
id pubmed-7745719
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-77457192020-12-18 Hormonal Receptors, Human Epidermal Growth Factor Receptor-2 and Triple Negative Immunohistochemical Typing in Women with Breast Cancer in Kampala, Uganda Mlole, Angela T Yahaya, James J Othieno, Emmanuel Kalungi, Sam Okwi, Andrew L Int J Womens Health Original Research BACKGROUND: The expression of estrogen and progesterone receptors (ER and PR) and human epidermal growth factor receptor-2 (HER2) has been reported to have an invaluable prognostic role. The aim of this study was to determine the expression of ER, PR and HER2 in women with breast cancer (BC) in Kampala, Uganda. METHODS: Expression of ER, PR and HER2 was determined immunohistochemically. Logistic regression was performed to determine the effect of the independent factors in predicting the risk of not expressing the breast markers. A two-tailed p<0.05 was regarded to be statistically significant. RESULTS: ER, PR and HER2 were expressed in 53.4%, 46.6% and 18.5%, respectively. ER and PR co-expression was present in 42.7% and 37.9% patients had triple negative breast cancer (TNBC). Age was an independent predictor of expression of ER (AOR = 0.18, 95% CI = 0.062–0.541, p = 0.002) and PR (AOR = 0.35, 95% CI = 0.129–0.968, p = 0.043). CONCLUSION: The majority of patients in this study had less than 50 years with high tumour grade. Interestingly, most of them had high expression of HER2 with TNBC which are molecular subtypes of BC with poor prognosis. Age was an independent predictor of expression of both ER and PR. Dove 2020-11-27 /pmc/articles/PMC7745719/ /pubmed/33343201 http://dx.doi.org/10.2147/IJWH.S270082 Text en © 2020 Mlole et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Mlole, Angela T
Yahaya, James J
Othieno, Emmanuel
Kalungi, Sam
Okwi, Andrew L
Hormonal Receptors, Human Epidermal Growth Factor Receptor-2 and Triple Negative Immunohistochemical Typing in Women with Breast Cancer in Kampala, Uganda
title Hormonal Receptors, Human Epidermal Growth Factor Receptor-2 and Triple Negative Immunohistochemical Typing in Women with Breast Cancer in Kampala, Uganda
title_full Hormonal Receptors, Human Epidermal Growth Factor Receptor-2 and Triple Negative Immunohistochemical Typing in Women with Breast Cancer in Kampala, Uganda
title_fullStr Hormonal Receptors, Human Epidermal Growth Factor Receptor-2 and Triple Negative Immunohistochemical Typing in Women with Breast Cancer in Kampala, Uganda
title_full_unstemmed Hormonal Receptors, Human Epidermal Growth Factor Receptor-2 and Triple Negative Immunohistochemical Typing in Women with Breast Cancer in Kampala, Uganda
title_short Hormonal Receptors, Human Epidermal Growth Factor Receptor-2 and Triple Negative Immunohistochemical Typing in Women with Breast Cancer in Kampala, Uganda
title_sort hormonal receptors, human epidermal growth factor receptor-2 and triple negative immunohistochemical typing in women with breast cancer in kampala, uganda
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745719/
https://www.ncbi.nlm.nih.gov/pubmed/33343201
http://dx.doi.org/10.2147/IJWH.S270082
work_keys_str_mv AT mloleangelat hormonalreceptorshumanepidermalgrowthfactorreceptor2andtriplenegativeimmunohistochemicaltypinginwomenwithbreastcancerinkampalauganda
AT yahayajamesj hormonalreceptorshumanepidermalgrowthfactorreceptor2andtriplenegativeimmunohistochemicaltypinginwomenwithbreastcancerinkampalauganda
AT othienoemmanuel hormonalreceptorshumanepidermalgrowthfactorreceptor2andtriplenegativeimmunohistochemicaltypinginwomenwithbreastcancerinkampalauganda
AT kalungisam hormonalreceptorshumanepidermalgrowthfactorreceptor2andtriplenegativeimmunohistochemicaltypinginwomenwithbreastcancerinkampalauganda
AT okwiandrewl hormonalreceptorshumanepidermalgrowthfactorreceptor2andtriplenegativeimmunohistochemicaltypinginwomenwithbreastcancerinkampalauganda